Chief Development Officer

Dr. David Bingaman has over 25 years of ophthalmic product expertise that spans the full development life cycle and therapeutic subspecialties. He used this knowledge as Chief Development Officer of Ora, where he oversaw regulatory, clinical, non-clinical, and CMC activities that directly impacted customers around the world. Before joining Ora, Dr. Bingaman served in large, public entities and small, privately held biotechnology companies. Prior employers include Alcon Laboratories, Alcon/Novartis, Oculis, and PanOptica. His passion for advancing science and medicine for patients with vision-threatening diseases has led to numerous successful clinical and non-clinical ophthalmic development strategies for early- and late-phase programs, while serving as a collaborative thought leader in the global ophthalmic community.  Dr. Bingaman is a board-certified Veterinary Ophthalmologist with a PhD in ocular angiogenesis, a patent-holder, and internationally recognized author and speaker.